Evidence map›Paper›PMID 39632755›Full record

ArticleBiomolecules & therapeutics2025

Design, Screening and Development of Asymmetric siRNAs Targeting the

Negesse Mekonnen, Myeung-Ryun Seo, Hobin Yang, Chaithanya Chelakkot, Jun Young Choi, Sungyoul Hong, Kyoung Song, Young Kee Shin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Negesse MekonnenResearch Institute of Pharmaceutical Science, Department of Pharmacy, Seoul National University, College of Pharmacy, Seoul 08826, Republic of Korea.
Myeung-Ryun SeoDepartment of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Graduate School of Convergence Science and Technology, Seoul 08826, Republic of Korea.
Hobin YangCollege of Pharmacy, Kyungsung University, Busan 48434, Republic of Korea.
Chaithanya ChelakkotResearch Institute of Pharmaceutical Science, Department of Pharmacy, Seoul National University, College of Pharmacy, Seoul 08826, Republic of Korea.
Jun Young ChoiR&D Center, ABION Inc., Seoul 08394, Republic of Korea.
Sungyoul HongResearch Institute of Pharmaceutical Science, Department of Pharmacy, Seoul National University, College of Pharmacy, Seoul 08826, Republic of Korea.
Kyoung SongCollege of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea.
Young Kee ShinResearch Institute of Pharmaceutical Science, Department of Pharmacy, Seoul National University, College of Pharmacy, Seoul 08826, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks hormone receptor and Her2 (ERBB2) expression, leaving chemotherapy as the only treatment option. The urgent need for targeted therapy for TNBC patients has led to the investigation of small interfering RNAs (siRNAs), which can target genes in a sequence-specific manner, unlike other drugs. However, the clinical translation of siRNAs has been hindered by the lack of an effective delivery system, except in the case of liver diseases. The MYC oncogene is commonly overexpressed in TNBC compared to other breast cancer subtypes. In this study, we used siRNA to target MYC in MDA-MB-231, MDA-MB-157, MDA-MB-436 and Hs-578T cells. We designed various symmetric and asymmetric (asiRNAs), screened them for

Indexed as

Asymmetric siRNAc-MYC oncogeneDocosanoic acid conjugationsiRNA modificationTargeted therapyTriple-negative breast cancer

Identifiers

PMID39632755
PMCPMC11704396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.